問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Thoracic Surgery

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

更新時間：2023-09-19

林孟志
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

79Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林孟志

List

158Cases

2018-05-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

江起陸
Taipei Veterans General Hospital

Division of Thoracic Medicine

2020-02-01 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  • Condition/Disease

    Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  • Test Drug

    TIRAGOLUMAB、ATEZOLIZUMAB

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2018-12-01 - 2027-12-31

Phase II/III

Active
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Tencentriq、Carboplatin-GRY、Cisplatin NeoCorp、Gitrabin、Alimta、Entrectinib、Cotellic、Zelboraf

Participate Sites
7Sites

Recruiting7Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

2007-11-14 - 2009-12-29

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2026-03-10 - 2029-05-24

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-08-20 - 2029-02-17

Phase III

Active
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)

  • Condition/Disease

    Non-Small Cell Lung Cancer、 Carcinoma, Non-Small-Cell Lung 、Carcinoma, Non-Small-Cell Lung (NSCLC)

  • Test Drug

    Frozen Crystal Injection Injection

Participate Sites
8Sites

Recruiting8Sites

2026-01-01 - 2028-01-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

2008-06-01 - 2012-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-01-01 - 2032-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2020-09-01 - 2028-12-31

Phase III

Active
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372 (Amivantamab) / JNJ-73841937 (Lazertinib)

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

1 2 3 4 5 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB